ThermoGenesis Holdings Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update
ThermoGenesis Holdings, Inc. (THMO) reported a 33% decrease in net revenues for Q3 2022, totaling $2.1 million, down from $3.2 million in Q3 2021, largely due to lower sales in China. Gross profit also fell to $0.4 million (21% of net revenue) from $1.1 million (35%). Selling, general, and administrative expenses increased to $2.0 million. The net loss widened to $3.2 million or ($0.10) per share. The company plans to launch a new cGMP compliant CDMO facility to address growing manufacturing needs in regenerative medicine.
- Plans to launch a new cGMP compliant CDMO facility to support industry manufacturing needs.
- Raised approximately $2.0 million in a public offering aiding transformation efforts.
- Net revenues decreased by 33% to $2.1 million due to lower sales.
- Gross profit decreased to $0.4 million, dropping to 21% of net revenue.
- Net loss increased to $3.2 million, compared to $1.8 million in Q3 2021.
Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET
RANCHO CORDOVA, Calif., Nov. 10, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the third quarter ended September 30, 2022 and provided a corporate strategic update.
"As more regenerative medicine treatments, such as CAR-T cell therapies, receive regulatory approval, the demand for manufacturing of these complex, lifesaving therapies continues to grow. This is true, both domestically and internationally, as only a small fraction of such drugs, whether for clinical trial or commercial use, are manufactured in-house. Given the increasing focus on this space, the limited number of good manufacturing practice (cGMP) facilities, serious technological inefficiencies, and high costs, coupled with severely limited global capacity, partnerships with CDMOs are on the rise," stated Chris Xu, Ph.D., Chief Executive Officer of ThermoGenesis.
"During the third quarter, we continued to make significant progress towards launching our TG Biosynthesis division, with the goal of creating a 35,745 square foot, state-of-the-art, cGMP compliant CDMO facility to support the industry's growing manufacturing requirements. As previously reported, we plan to leverage our proprietary high efficiency, semi-automated CAR-TXpress™ platform, which we believe is capable of meaningfully reducing processing time, improving cell recovery, and potentially cutting the manufacturing costs associated with CAR-T and other cell and gene therapies. We recently raised approximately
Financial Results for the Quarter Ended September 30, 2022
Net revenues. Net revenues for the quarter ended September 30, 2022, were
Gross profit. Gross profit for the quarter ended September 30, 2022 was
Selling, general and administrative expenses. Selling, general and administrative expenses were
Research and development expenses. Research and development expenses were
Interest expense. Interest expense for the quarter ended September 30, 2022, was
Net loss. For the quarter ended September 30, 2022, the Company reported a comprehensive loss attributable to common stockholders of
Liquidity and capital resources. At September 30, 2022, the Company had cash and cash equivalents totaling
Conference Call and Webcast Information
ThermoGenesis will host a conference call today at 1:30 p.m. PT/4:30 p.m. ET. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please visit: https://thermogenesis.com/investors/news-and-events/events-webcasts.
A webcast replay will also be available on ThermoGenesis' website for three months. To access the replay, please visit: https://thermogenesis.com/investors/news-and-events/events-webcasts.
About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: www.thermogenesis.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained herein. When used in this press release, the words "anticipate," "believe," "estimate," "expect" and similar expressions as they relate to the Company, or its management are intended to identify such forward-looking statements. Actual results, performance or achievements could differ materially from the results expressed in or implied by these forward-looking statements. Readers should be aware of important factors that, in some cases, have affected, and in the future could affect, actual results to differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. These factors include without limitation, the ability to obtain capital and other financing in the amounts and at the times needed to launch new products, market acceptance of new products, the nature and timing of regulatory approvals for both new products and existing products for which the Company proposes new claims, realization of forecasted revenues, expenses and income, initiatives by competitors, price pressures, failure to meet FDA regulated requirements governing the Company's products and operations (including the potential for product recalls associated with such regulations), risks associated with initiating manufacturing for new products, failure to meet Foreign Corrupt Practice Act regulations, legal proceedings, risks associated with expanding into the Company's planned CDMO business, uncertainty associated with the COVID-19 pandemic, and other risk factors listed from time to time in our reports with the Securities and Exchange Commission ("SEC"), including, in particular, those set forth in ThermoGenesis Holdings' Form 10-K for the year ended December 31, 2021.
Company Contact:
Wendy Samford
916-858-5191
ir@thermogenesis.com
Investor Contact:
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com
Financials
ThermoGenesis Holdings, Inc. Condensed Consolidated Balance Sheets | ||||||
September 30, 2022 | December 31, 2021 | |||||
(Unaudited) | ||||||
ASSETS | ||||||
Current assets: | ||||||
Cash and cash equivalents | ||||||
Accounts receivable, net | 2,056,000 | 733,000 | ||||
Inventories | 4,912,000 | 5,373,000 | ||||
Prepaid expenses and other current assets | 612,000 | 1,578,000 | ||||
Total current assets | 11,483,000 | 14,964,000 | ||||
Inventories non-current, net | 930,000 | 1,709,000 | ||||
Equipment and leasehold improvements, net | 1,271,000 | 1,261,000 | ||||
Right-of-use operating lease assets, net | 426,000 | 571,000 | ||||
Right-of-use operating lease assets – related party, net | 3,653,000 | -- | ||||
Goodwill | 781,000 | 781,000 | ||||
Other intangible assets, net | 1,294,000 | 1,318,000 | ||||
Other assets | 255,000 | 48,000 | ||||
Total assets | ||||||
LIABILITIES AND EQUITY | ||||||
Current liabilities: | ||||||
Accounts payable | ||||||
Other current liabilities | 9,961,000 | 5,068,000 | ||||
Total current liabilities | 10,968,000 | 6,348,000 | ||||
Long-term liabilities | 4,859,000 | 10,907,000 | ||||
ThermoGenesis Holdings, Inc. stockholders' equity | 5,099,000 | 3,828,000 | ||||
Noncontrolling interests | (833,000) | (431,000) | ||||
Total liabilities and equity | ||||||
ThermoGenesis Holdings, Inc. Condensed Consolidated Statements of Operations (Unaudited) | ||||||||
Three Months Ended | Nine Months Ended | |||||||
2022 | 2021 | 2022 | 2021 | |||||
Net revenues | ||||||||
Cost of revenues | 1,678,000 | 2,043,000 | 5,491,000 | 4,067,000 | ||||
Gross profit | 437,000 | 1,115,000 | 2,316,000 | 2,809,000 | ||||
Expenses: | ||||||||
Selling, general and administrative | 1,982,000 | 1,677,000 | 5,665,000 | 7,171,000 | ||||
Research and development | 470,000 | 543,000 | 1,317,000 | 1,544,000 | ||||
Total operating expenses | 2,452,000 | 2,220,000 | 6,982,000 | 8,715,000 | ||||
Loss from operations | (2,015,000) | (1,105,000) | (4,666,000) | (5,906,000) | ||||
Other expenses | ||||||||
Interest expense | (1,391,000) | (1,530,000) | (3,572,000) | (4,573,000) | ||||
Other income (expense) | 3,000 | 843,000 | (1,000) | 833,000 | ||||
Gain on extinguishment of debt | -- | -- | -- | 652,000 | ||||
Total other expense | (1,388,000) | (687,000) | (3,573,000) | (3,088,000) | ||||
Net loss | (3,403,000) | (1,792,000) | (8,239,000) | (8,994,000) | ||||
Loss attributable to noncontrolling interests | (163,000) | (18,000) | (402,000) | (269,000) | ||||
Net loss attributable to common stockholders | ||||||||
ThermoGenesis Holdings, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) | ||||
Nine Months Ended September 30, | ||||
2022 | 2021 | |||
Cash flows from operating activities: | ||||
Net cash used in operating activities | ||||
Cash flows from investing activities: | ||||
Capital expenditures | (308,000) | (64,000) | ||
Cash flows from financing activities: | ||||
Proceeds from issuance of common stock, net of expenses | 3,037,000 | 6,832,000 | ||
Effects of foreign currency rate changes on cash and cash equivalents | (5,000) | (1,000) | ||
Net increase (decrease) in cash, cash equivalents and restricted cash | (3,377,000) | 473,000 | ||
Cash, cash equivalents and restricted cash at beginning of period | 7,280,000 | 7,161,000 | ||
Cash, cash equivalents and restricted cash at end of period | ||||
View original content:https://www.prnewswire.com/news-releases/thermogenesis-holdings-announces-financial-results-for-the-third-quarter-ended-september-30-2022-and-provides-corporate-update-301674988.html
SOURCE ThermoGenesis Holdings, Inc.
FAQ
What were the financial results for ThermoGenesis Holdings (THMO) in Q3 2022?
Why did ThermoGenesis (THMO) experience a decrease in revenues in Q3 2022?
What is the future outlook for ThermoGenesis Holdings (THMO)?
